Search results
Results from the WOW.Com Content Network
Saroglitazar is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. In clinical studies, saroglitazar has demonstrated reduction of triglycerides (TG), LDL cholesterol , VLDL cholesterol, non-HDL cholesterol and an increase in HDL cholesterol a ...
Most type 2 diabetes injections for weight loss are glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs mimic the GLP-1 hormone, which is made in your gastrointestinal tract when you ...
Type 2 diabetes is the most common type of diabetes. Treatments include agents that (1) increase the amount of insulin secreted by the pancreas, (2) increase the sensitivity of target organs to insulin, (3) decrease the rate at which glucose is absorbed from the gastrointestinal tract, and (4) increase the loss of glucose through urination.
Drug-free weight loss options like eating nutritious foods and doing more movement. ... It’s used as a diabetes drug, but again, it can be prescribed off-label for weight loss. For type 2 ...
The main goal of diabetes management is to keep blood glucose (BG) levels as normal as possible. [1] If diabetes is not well controlled, further challenges to health may occur. [1] People with diabetes can measure blood sugar by various methods, such as with a BG meter or a continuous glucose monitor, which monitors over several days. [2]
The U.S. Food and Drug Administration initially approved Ozempic to treat Type 2 diabetes.
Levonadifloxacin (trade name Emrok) is an antibiotic drug of the fluoroquinolone class. [1] [2] Chemically, it is the (S)-enantiomer of the racemic drug nadifloxacin.It is approved in India for the treatment of skin and soft tissue infections of Gram-positive bacteria. [3]
For type 1 diabetics, there is a lack of definitive evidence of the usefulness of low-carbohydrate diets due to limited study of this topic. [1] [11] [12] A meta-analysis published in 2018 found only nine papers that had adequately studied the implementation of low carbohydrate diets in type 1 diabetics as of March 2017. [12]